Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | UBE2M | P61081 | 1/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472931 | 0.89 | PIK3CD (0.45) | PIK3CDMEN1KMT2ALMNAUBE2M | |
| SCHEMBL22449312 | 0.85 | PIK3CD (0.49) | PIK3CDMEN1KMT2ALMNA | |
| SCHEMBL22472891 | 0.85 | HCRTR2 (0.31) | HCRTR2 | |
| SCHEMBL22472946 | 0.83 | HCRTR2 (0.30) | HCRTR2 | |
| SCHEMBL22472898 | 0.81 | CHRM1 (0.31) | — | |
| SCHEMBL22472874 | 0.80 | CCR5 (0.44) | MEN1KMT2AUBE2MDCUN1D1 | |
| SCHEMBL21597935 | 0.75 | PIK3CD (0.48) | PIK3CDLMNAUBE2MDCUN1D1 | |
| SCHEMBL22472871 | 0.74 | CHRM1 (0.35) | TP53 | |
| SCHEMBL27176070 | 0.74 | PIK3CD (0.52) | PIK3CDMEN1KMT2A | |
| SCHEMBL22472879 | 0.73 | EPHX2 (0.39) | HCRTR2KMT2ALMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | PIK3CD 2063/4885HCRTR2 194/4885MEN1 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.